Make an application to the InhibOx/NFCR virtual screening service

The website of our FP6 consortium
InhibOx works closely with MolPort

Jussi is a theoretical physicist who began his academic career at McGill University, Montreal before moving to the University of Helsinki and more recently, the University of Oxford. His enduring scientific interests lie in the fields of simulation of complex systems, distributed computing and molecular physics.

Paul completed his undergraduate degree at St Peter's College Oxford and his biochemistry Ph.D at the University of Manchester. Between 1985 and 1990 he worked as a scientist in the computational chemistry group at SmithKline Beecham, where he focused on the discovery of novel antibiotic agents. In 1990 he moved to Pfizer's computational chemistry group where he was responsible for developing Pfizer's in-house approach to virtual screening.
In 1998, Paul joined Prolifix, a UK biotechnology company which was acquired in 2002 by TopoTarget, a listed drug development company focused on oncology. Following this acquisition Paul became group director of R&D and was responsible for TopoTarget's extremely successful HDAC inhibitor programme (now in multiple phase II trials).

John read law at the University of Oxford and went on to complete a masters degree at McGill University. He returned to the UK in 1996 and trained as a chartered accountant in London with Robson Rhodes. In 1999 he became finance director of IndexIT Partnership Ltd, a technology advisory boutique, which was acquired in 2000 for £36 million by Beeson Gregory Group plc, an investment bank. At Beeson Gregory he worked in the bank's private equity team, which specialised in financing early stage technology companies.

Between 2001 and 2005, John was CFO of IP Group plc, the UK's leading intellectual property commercialization company. During his tenure, IP Group plc raised three private rounds of finance, listed on the AIM market raising £30 million and grew 10 times its original value to £250 million. John was integral to most of the company's major activities, including the structuring of its long term partnerships with UK universities, the formation of spin out companies from these partnerships and the group's acquisitions.

Professor W. Graham Richards is one of the leading computational chemists in the UK, with over 300 publications.  He served as chairman of the Department of Chemistry at Oxford University from 1997 to 2007. He is head of the Centre for Computational Drug Discovery at Oxford. Throughout his career, Professor Richards has been involved in the commercialisation of technologies. In 1989, he co-founded Oxford Molecular Ltd, which later floated on the London Stock Exchange as Oxford Molecular Group plc. In 2001, he founded InhibOx Ltd. He was a director of ISIS Innovation Ltd, the University of Oxford's technology transfer company and was involved for several years with the Wellcome Trust in a similar capacity. He is a main board director (formerly chairman) of IP Group plc, the listed intellectual property commercialization company.

Barry has over twenty years of drug discovery experience working in the pharmaceutical industry. He was chief executive of ReOx, a biotechnology spin out from the University of Oxford, a non-executive director of Curidium and recently director and senior vice president drug discovery at De Novo pharmaceuticals. Prior to that Barry held senior positions at Pharmagene (vice president therapeutics), Rhone-Poulenc Rorer (senior director of medicinal chemistry) and Glaxo Group Research (research leader). He gained his PhD from the University of California, San Diego followed by a post doctoral fellowship with Syntex in Palo Alto.